BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol 2021;18:591-602. [PMID: 33976418 DOI: 10.1038/s41571-021-00508-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pol J, Paillet J, Plantureux C, Kroemer G. Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases. OncoImmunology 2022;11:2029299. [DOI: 10.1080/2162402x.2022.2029299] [Reference Citation Analysis]
2 Petrazzuolo A, Perez-Lanzon M, Liu P, Maiuri MC, Kroemer G. Crizotinib and ceritinib trigger immunogenic cell death via on-target effects. Oncoimmunology 2021;10:1973197. [PMID: 34712511 DOI: 10.1080/2162402X.2021.1973197] [Reference Citation Analysis]
3 Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylösmäki E, Bonini C, Ruggiero E, Hamdan F, Feodoroff M, Antignani G, Viitala T, Pesonen S, Grönholm M, Branca RMM, Lehtiö J, Cerullo V. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Elife 2022;11:e71156. [PMID: 35314027 DOI: 10.7554/eLife.71156] [Reference Citation Analysis]
4 Pol JG, Paillet J, Plantureux C, Kroemer G. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. Oncoimmunology 2021;10:1968595. [PMID: 34527429 DOI: 10.1080/2162402X.2021.1968595] [Reference Citation Analysis]
5 Giuliani C, Verrocchio S, Verginelli F, Bucci I, Grassadonia A, Napolitano G. Hormonal Regulation of the MHC Class I Gene in Thyroid Cells: Role of the Promoter "Tissue-Specific" Region. Front Endocrinol (Lausanne) 2021;12:749609. [PMID: 34938270 DOI: 10.3389/fendo.2021.749609] [Reference Citation Analysis]
6 Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, Ly P, Fidelle M, Mazzenga M, Costa Silva CA, Armanini F, Pinto F, Asnicar F, Daillère R, Derosa L, Richard C, Blanchard P, Routy B, Culine S, Opolon P, Silvin A, Ginhoux F, Toubert A, Segata N, McNeel DG, Fizazi K, Kroemer G, Zitvogel L. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer 2022;10:e004191. [PMID: 35296557 DOI: 10.1136/jitc-2021-004191] [Reference Citation Analysis]
7 Zitvogel L, Kroemer G. Cross-reactivity between microbial and tumor antigens. Current Opinion in Immunology 2022;75:102171. [DOI: 10.1016/j.coi.2022.102171] [Reference Citation Analysis]
8 Rähni A, Jaago M, Sadam H, Pupina N, Pihlak A, Tuvikene J, Annuk M, Mägi A, Timmusk T, Ghaemmaghami AM, Palm K. Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies. Commun Med 2022;2. [DOI: 10.1038/s43856-022-00114-7] [Reference Citation Analysis]
9 Ulisse S, Baldini E, Lauro A, Pironi D, Tripodi D, Lori E, Ferent IC, Amabile MI, Catania A, Di Matteo FM, Forte F, Santoro A, Palumbo P, D'Andrea V, Sorrenti S. Papillary Thyroid Cancer Prognosis: An Evolving Field. Cancers (Basel) 2021;13:5567. [PMID: 34771729 DOI: 10.3390/cancers13215567] [Reference Citation Analysis]
10 Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 2022. [PMID: 35393541 DOI: 10.1038/s41568-022-00466-1] [Reference Citation Analysis]
11 Roberti MP, Rauber C, Kroemer G, Zitvogel L. Impact of the ileal microbiota on colon cancer. Semin Cancer Biol 2021:S1044-579X(21)00250-9. [PMID: 34624451 DOI: 10.1016/j.semcancer.2021.09.016] [Reference Citation Analysis]
12 Zhang Y, Xie Y, Feng Y, Wang Y, Xu X, Zhu S, Xu F, Feng N. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner. Gene 2022;808:145966. [PMID: 34530089 DOI: 10.1016/j.gene.2021.145966] [Reference Citation Analysis]
13 Feola S, Haapala M, Peltonen K, Capasso C, Martins B, Antignani G, Federico A, Pietiäinen V, Chiaro J, Feodoroff M, Russo S, Rannikko A, Fusciello M, Koskela S, Partanen J, Hamdan F, Tähkä SM, Ylösmäki E, Greco D, Grönholm M, Kekarainen T, Eshaghi M, Gurvich OL, Ylä-Herttuala S, M Branca RM, Lehtiö J, Sikanen TM, Cerullo V. PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. ACS Nano 2021;15:15992-6010. [PMID: 34605646 DOI: 10.1021/acsnano.1c04371] [Reference Citation Analysis]
14 Jacqueline C, Dracz M, Boothman S, Minden JS, Gottschalk RA, Finn OJ. Identification of Cell Surface Molecules That Determine the Macrophage Activation Threshold Associated With an Early Stage of Malignant Transformation. Front Immunol 2021;12:749597. [PMID: 34712237 DOI: 10.3389/fimmu.2021.749597] [Reference Citation Analysis]
15 Verkhovskaia S, Di Pietro FR, Mastroeni S, Carbone ML, Abeni D, Morese R, Morelli FM, D'Atri S, Marchetti P, De Galitiis F, Failla CM, Fortes C. Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. J Cancer Res Clin Oncol 2021. [PMID: 34595541 DOI: 10.1007/s00432-021-03811-3] [Reference Citation Analysis]
16 Paschou SA, Liontos M, Eleftherakis-papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos M. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol 2022;12:847917. [DOI: 10.3389/fonc.2022.847917] [Reference Citation Analysis]
17 Motofei IG. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opin Drug Saf 2021;:1-14. [PMID: 34937484 DOI: 10.1080/14740338.2022.2020243] [Reference Citation Analysis]
18 Scatozza F, Facchiano A. Expression of Autoimmunity-Related Genes in Melanoma. Cancers 2022;14:991. [DOI: 10.3390/cancers14040991] [Reference Citation Analysis]
19 Joseph A, Pan J, Michels J, Kroemer G, Castedo M. Pyridoxal kinase and poly(ADP-ribose) affect the immune microenvironment of locally advanced cancers. Oncoimmunology 2021;10:1950954. [PMID: 34290910 DOI: 10.1080/2162402X.2021.1950954] [Reference Citation Analysis]
20 Jacqueline C, Dracz M, Xue J, Binder RJ, Minden J, Finn O. LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors. OncoImmunology 2022;11:2029083. [DOI: 10.1080/2162402x.2022.2029083] [Reference Citation Analysis]
21 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol 2022. [PMID: 35145297 DOI: 10.1038/s41590-022-01132-2] [Reference Citation Analysis]